经导管封堵动脉导管未闭介入治疗后残余分流

目的探讨经导管封堵动脉导管未闭(PDA)介入治疗后残余分流的可行性和临床疗效。方法自1997年3月至2001年8月16例PDA介入治疗后残余分流的患者,其中男4例,女12例,平均年龄5.9±2.4岁(2～9岁),平均体重17.7±5.4kg(9～28kg),应用不同介入方法经动脉或静脉途径封堵残余分流,首次介入治疗与再次介入治疗的时间间隔平均为1.5±1.1年(1天～3.5年)。结果残余分流直径平均为2.7±0.9mm(1.2～5.0mm)。15例成功完成残余分流封堵术,1例失败,技术成功率为94%(15/16)。单纯应用Cook可控弹簧圈9例(其中双弹簧圈2例),Rashkind双面伞2例,Sidris纽扣式补片1例,Amplatzer蘑菇伞2例,同时应用Cook可控弹簧圈和Sidris纽扣式补片1例。封堵术后即刻造影,3例仍有少量残余分流,完全闭合率为80%(12/15)。平均手术时间为75.0±22.8min(45～120min),平均X线透视时间为10.4±3.9min(5～20min)。股动脉并发症1例,其余无并发症出现。封堵术后24h复查超声心动图,所有残余分流均完全闭合(100%),在平均2年随访中未出现残余分流再通、封堵器移位和左右肺动脉狭窄。结论经导管封堵PDA介入治疗后残余分流安全、疗效确切、创伤小,可作为外科手术治疗PDA介入治疗后残余分流的一种替代方法。     

高原地区用Amplatzer封堵器治疗动脉导管未闭

目的:应用Amplatzer封堵器在高原地区治疗动脉导管未闭(PDA)并评价其疗效。方法:本组40例,年龄1.5～44(22.5±14.2)岁,PDA最窄处内径5～14(9.3±3.3)mm,均用Amplatzer封堵器介入治疗。结果:19例成功,1例严重阻塞性肺动脉高压不适宜封堵。术后即刻降主动脉造影显示35例封堵完全无残余分流,4例少量残余分流。1例术后1h封堵器脱落入右肺动脉,第3小时急诊外科手术关闭PDA并取出封堵器。24 h彩色多普勒检查显示封堵36例患者均无分流,随访2个月～1年半,无一例分流。结论:高原地区PDA发病率高,并发肺动脉高压早且多,巨大PDA(内径>0.8 cm)比率高,用Amplatzer封堵器治疗PDA是高原地区一种适应性强、安全有效的介入治疗方法。     

动脉导管未闭合并重度肺动脉高压Amplatzer法封堵治疗的临床应用--12例初步报告

目的评价Amplatzer封堵器治疗动脉导管未闭(PDA)合并重度肺动脉高压(SPH)的初步疗效.方法对12例(女9例,男3例)PDA合并SPH患者实施封堵治疗.其中10例采用Amplatzer动脉导管未闭封堵器,2例采用Amplatzer房间隔缺损封堵器.结果全组12例PDA封堵器均放置成功.11例PDA封堵后30分至1小时肺动脉收缩压、肺动脉平均压均明显降低.1例封堵术后即刻肺动脉压无变化.术后36小时彩色多普勒估测肺动脉压明显下降,封堵术后30分降主动脉造影,无残余分流9例,微量残余分流2例,少量残余分流1例.全组术后24～48小时彩色多普勒检查,动脉水平左向右分流均完全消失.无重要并发症发生.随访1～24个月(平均8个月),患者症状改善,11例心脏缩小,无1例发生再通.结论采用Amplatzer法封堵治疗PDA合并SPH,近期疗效满意.     

用Amplatzer封堵器介入治疗房间隔缺损及动脉导管未闭(附23例报告)

目的　探讨应用Amplatzer封堵器治疗先天性心脏病心房间隔缺损 (atrialseptaldefect,ASD)及动脉导管未闭 (patentductusarteriosus ,PDA)的方法并评价其疗效。方法　 2 3例患者 (ASD 19例 ,PDA 4例 )。所有病例均在X线透视、造影及食道超声心动图监视下经导管置入Amplatzer封堵器治疗ASD及PDA。结果　全组技术成功率 10 0 %。 2 3例患者术后 2 4h、1周行经胸超声心动图 (TTE)检查 ,有 2例存在残余分流 ,术后即刻完全封堵率 91 2 %。术后 6个月随访TTE检查示所有病例均封堵完全 ,无残余分流 ;X线检查全部显示肺血减少 ,心胸比例不同程度缩小。结论　经导管置入Amp latzer封堵器是治疗ASD和PDA的一种操作简便、技术成功率高、疗效可靠的介入方法。     

高原地区用Amplatzer封堵器介入治疗动脉导管未闭

目的 :应用 Amplatzer封堵器在高原地区治疗动脉导管未闭 （PDA）并评价其疗效。方法 :本组 2 0例 ,年龄 1.5～ 44 （2 2± 14）岁 ,PDA最窄处内径 5～ 14（9± 3） m m,均用 Am platzer封堵器介入治疗。结果 :19例成功 ,1例严重阻力性肺动脉高压不适宜封堵。术后即刻降主动脉造影显示 15例封堵完全无残余分流 ,4例少量残余分流。 1例术后 1h封堵器脱落入右肺动脉 ,第三小时急诊外科手术关闭 PDA并取出封堵器。 2 4h彩色多普勒检查显示封堵 18例患者均无分流 ,随访 2月～ 1.5年 ,无 1例分流。结论 :用 Amplatzer封堵器治疗 PDA是高原地区 1种适应性强 ,安全有效的介入治疗方法。     

Amplatzer房间隔封堵器在巨大窗型动脉导管未闭封堵术中的应用

自 Porstmann等应用 Ivalon海绵塞子封堵动脉导管未闭 ( PDA)获得成功以来 ,应用介入疗法封堵PDA技术已在国内外广泛开展 ,如 Rashkind等伞型封堵器、Sideris钮扣式补片、弹簧圈等。但由于多需较大的传送装置 ,或有残余分流 ,往往仅用于内径较小的 PDA。 1 996年 Masura等 [1]应用 Amplatazer蘑菇伞封堵器封堵 PDA成功后 ,将 PDA可封堵的内径提高到 1 2 mm。 2 0 0 1年我们采用 Amplatzer房间隔封堵器封堵巨大窗型 PDA2例。现报告如下。1　资料与方法1 .1　临床资料　例 1 :女 ,1 6岁 ,体重 36kg。胸骨左缘第二肋间闻及 4/6级连续…     

国产动脉导管未闭封堵器与Amplatzer封堵器在经动脉导管未闭封堵术中应用的疗效比较

目的比较国产动脉导管未闭封堵器与Amplatzer封堵器(美国进口)在经动脉导管未闭(PDA)封堵术中应用的疗效。方法对2006年1月至12月广东省人民医院确诊为PDA的206例患者,110例采用国产封堵器,96例采用Amplatzer封堵器,分别进行PDA封堵术,对比两组的疗效、并发症和费用等情况。结果国产组109例封堵成功(成功率99.1%),进口组95例封堵成功(成功率99.0%)。两组PDA术前各项临床资料指标、手术和X线曝光时间、封堵成功率及住院天数、术后各项并发症发生率比较,差异无显著性意义,两组PDA治疗前后左室舒张末压及心胸比率降低程度差异无显著性意义,治疗总费用国产组明显低于进口组。结论国产PDA封堵器与Amplatzer封堵器相比其疗效、并发症发生率差异无显著性意义,治疗费用低,临床应用前景广泛。     

应用Amplatzer封堵器经导管治疗直径≥8mm动脉导管未闭的疗效评价

目的 :应用 Amplatzer封堵器经导管治疗直径≥ 8mm的大型动脉导管未闭 （PDA）并对其疗效进行评价。方法 :全组 5 0例 ,年龄 2 6 .4± 2 3.2 （4.0～ 6 0 .0 ）岁。 PDA最窄处直径为 10 .2± 2 .3（8.0～ 15 .0 ） mm。封堵 10 m in后行侧位降主动脉造影 ,术后 1d及 1月行超声心动图检查 ,观察有无残余分流及 PDA再通。结果 :47例 PDA采用Amplatzer PDA封堵器治疗 ,2例采用 Amplatzer ASD封堵器治疗 ,1例 PDA伴有阻力性肺动脉高压未行介入治疗。术后 10 min降主动脉造影显示 ,19例存在微～少量残余分流 ,30例封堵完全无残余分流。术后 2 4h、术后 1月超声心动图未见残余分流及再通。结论 :应用 Am platzer封堵器治疗直径≥ 8mm的大型动脉导管未闭是一种安全有效的介入方法。     

经导管封堵动脉导管未闭外科及介入治疗术后残余分流

目的 评价经导管封堵动脉导管未闭(PDA)外科结扎及介入治疗术后残余分流的效果.方法 1995年6月至2008年9月,42例外科结扎、1例外科结扎术后又行弹簧栓子法、3例Rashkind法及1例Sidires法介入治疗术后残余分流的PDA患者施行了经导管封堵术,其中男9例,女38例,年龄2～53岁,平均25.0±15.5岁.外科手术至介入治疗的时间为1个月～30年,其中1例曾行两次外科结扎术.第一次介入治疗至本次封堵术的时间为4年～14年.43例经股静脉途径植入封堵器,其中2例采用动静脉轨道法;2例经股动脉途径植入可控弹簧栓子.介入术后24 h～7.8年行X线胸片、心电图及超声心动图随访.结果 残余分流的PDA最窄处直径为1～10 mm,平均4.1±2.0 mm.技术成功率为95.7%(45/47).45例封堵术后10 min.主动脉弓降部造影示无残余分流40例(88.9%),微量残余分流4例(8.9%),少量残余分流1例(2.2%).术后24 h经胸超声心动图示无残余分流44例(97.8%),少量残余分流1例(2.2%),该例术后9 h发生溶血,经保守治疗1周后消失.失败2例,植入封堵器后仍有明显残余分流,收回封堵器,终止介入治疗.本组45例随访1个月～7.8年,除1例于术后4个月发生心房颤动外,余未发现封堵器移位、残余分流及细菌性心内膜炎.结论 经导管封堵动脉导管未闭外科结扎及介入治疗术后的残余分流是一种创伤小、成功率高、并发症少、住院时间短、安全有效的方法,基本可以替代外科手术.     

国产Amplatzer封堵器治疗先天性房间隔缺损

目的应用国产Amplatzer封堵器治疗先天性房间隔缺损(ASD)并评价其疗效。方法12例ASD患者行Amplatzer封堵术,均在经胸超声心动图(UCG)及透视监测下用Amplatzer封堵器介入治疗。结果12例均获成功,技术成功率100%。术后即刻UCG显示2例存在少量残余分流,分别于1个月后、3个月后UCG显示残余分流消失,即刻完全封堵率达83.3%。随访2个月至1年,无残余分流及封堵器脱落,肺多血及右心房室增大较术前有不同程度的改善。结论在UCG指导下应用Amplatzer封堵器治疗ASD是一种有效的介入治疗方法。     

The Design and Deployment of the HELEX Septal Occluder

The GORE HELEX Septal Occluder? (W.L. Gore and Associates, Flagstaff, Ariz, USA) is the latest device to pursue U.S. Food and Drug Administration (FDA) approval for the closure of secundum atrial septal defects. The device is soft and compliant with comparatively little metal framework. It can be deployed and retrieved without damaging the device, and has a safety cord attached that allows retrieval even after it has been disconnected from the delivery mandrel. With FDA approval, operators will now have a choice of devices for the closure of atrial septal defects. Significant differences exist between the HELEX device and existing atrial septal occluders. This article explains the HELEX device design, provides recommendations for preprocedural screening and preparation, and discusses the deployment technique in detail. The device may be particularly advantageous for patients with small‐ to moderate‐sized atrial septal defects.     

Left-Atrial-Appendage Occluder Migrates in an Asymptomatic Patient

Percutaneous closure of the left atrial appendage (LAA) is a new approach to the prevention of cardioembolic events in patients with atrial fibrillation. We implanted an LAA occlusion device (Amplatzer™ Cardiac Plug) in a 70-year-old woman via a transseptal approach. Upon her discharge from the hospital, a transthoracic echocardiogram showed stable anchoring of the device; 6 months after implantation, a routine transthoracic echocardiogram revealed migration of the occluder into the left ventricular outflow tract, in the absence of symptoms. We surgically removed the device from the mitral subvalvular apparatus and closed the LAA with sutures. This case shows that percutaneous LAA occlusion can result in serious adverse events, including device migration in the absence of signs or symptoms; therefore, careful follow-up monitoring is mandatory.     

Transcatheter Retrieval of Embolized AMPLATZER Septal Occluder

In selected patients, transcatheter closure of atrial septal defects with the AMPLATZER Septal Occluder has yielded excellent results. However, there is a slight risk of device embolization after deployment. We report the case of a 26-year-old woman in whom an embolized AMPLATZER device was retrieved percutaneously from the right pulmonary artery. We also discuss important technical principles for managing this uncommon but potentially severe complication.Key words: Device removal/methods, embolization, therapeutic/instrumentation, heart catheterization/instrumentation, heart septal defects, atrial/ultrasonography, patient selection, prosthesis implantation/adverse effects, prostheses and implants, septal occluder device/adverse effects, treatment outcomeTranscatheter closure of atrial septal defects (ASDs) with use of the AMPLATZER® Septal Occluder (St. Jude Medical, Inc.; St. Paul, Minn) has yielded excellent results in properly selected patients.^1,2 The major advantage of the AMPLATZER occluder is its easy retrieval at all stages of deployment before its final release from the delivery cable. Although embolization of AMPLATZER ASD occluders is rare, it can occur even when interventional cardiologists are experienced. Despite an earlier belief that the transcatheter retrieval of embolized AMPLATZER devices would be difficult, success rates from 50% to 75% have been reported.^3,4 We describe the retrieval of an embolized AMPLATZER device in a young woman. In addition, we present some technical principles with which operators practicing device closure should be familiar.     

Transcatheter Closure of Patent Ductus Arteriosus Using the Amplatzer Duct Occluder

The Amplatzer duct occluder (ADO) (AGA Medical Corp., Golden Valley, MN) is designed to meet criteria for an optimal transcatheter technique for closure of a patent ductus arteriosus. It was developed as an alternative to surgical closure and other interventional techniques. It is not technically complex, allows controlled deployment, is retrievable and repositionable, and has a low risk of embolization. The ADO also has very high complete closure rate at 1-month follow-up comparable to surgical ligation and division.     

Amplatzer Septal Occluder to treat iatrogenic cardiac perforations

Background : Iatrogenic free wall cardiac perforation is a rare but serious complication encountered during percutaneous cardiac procedures, which usually leads to tamponade and death. Septal occluder devices have been developed for sealing intracardiac shunts but may be also used in this emergency setting. Methods and Results : We report a small series of five consecutive cases of iatrogenic heart perforations that were treated with implantation of Amplatzer Septal Occluders (ASO). In the first case, iatrogenic left ventricle (LV) perforation occurred during LV biopsy and could be closed up with a 4 mm ASO. In the second case, a 4 mm ASO was used for sealing of a right atrial perforation allocated to Port‐a‐Cath dislodgment. The third case happened during transseptal puncture for implantation of a TandemHeart bVAD device in a patient suffering cardiogenic shock and was treated by implantation of a 5 mm ASO. The fourth patient was transferred to our facilities for percutaneous closure of an acute post‐infarct VSD after anteroseptal myocardial infarction. This procedure was complicated by perforation of the posterolateral free wall and led to the deployment of 12 mm ASO. The last patient suffered from free LV wall perforation during investigation of a severe aortic stenosis and was treated by implantation of 4 mm ASO. All patients were alive after 24 hrs but the last patient died during the in‐hospital stay of a right ventricular infarction complicated by multiple organ failure. Conclusions : Percutaneous device occlusion of iatrogenic heart perforation seems to be a safe and efficient method to treat iatrogenic heart perforation. In order to perform this elegant method, it is however imperative not to prematurely withdraw the perforating catheter to maintain access to the hole for closure. © 2011 Wiley Periodicals, Inc.